Alexion enters RNA gene-silencing field with $637M Dicerna deal
October 24, 2018 at 10:46 AM EDT
Newly Massachusetts-based biotech Alexion Pharmaceuticals became the latest company to enter the gene silencing drug field, signing a deal with Dicerna Pharmaceuticals worth upwards of $637 million.